KRYS - Krystal Biotech, Inc.
253.69
-6.640 -2.617%
Share volume: 244,393
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.19%
PREVIOUS CLOSE
CHG
CHG%
$260.33
-6.64
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-06-2024 | 08-05-2024 | 11-04-2024 | 02-19-2025 | 05-06-2025 | 08-04-2025 | 11-03-2025 | 02-17-2026 | |
| Assets | |||||||||
| Total Assets | 853.296 M | 917.658 M | 982.318 M | 1.056 B | 1.074 B | 1.138 B | 1.240 B | 1.334 B | |
| Current Assets | 602.248 M | 682.772 M | 713.164 M | 742.045 M | 766.798 M | 841.347 M | 925.650 M | 1.025 B | |
| Inventories | 11.037 M | 12.179 M | 18.581 M | 26.508 M | 29.942 M | 31.041 M | 37.632 M | 40.475 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 179.253 M | 213.826 M | 214.358 M | 252.652 M | 308.076 M | 328.157 M | 338.465 M | 331.487 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 359.006 M | 345.786 M | 373.966 M | 344.865 M | 308.770 M | 353.829 M | 392.604 M | 496.304 M | |
| Total Non-current Assets | 83.996 M | 69.292 M | 105.888 M | 152.114 M | 148.472 M | 138.807 M | 133.113 M | 128.066 M | |
| Property Plant Equipment | 160.011 M | 158.808 M | 156.592 M | 155.168 M | 151.070 M | 150.388 M | 148.871 M | 150.776 M | |
| Other Assets | 91.037 M | 76.078 M | 112.562 M | 158.625 M | 156.548 M | 146.659 M | 165.573 M | 158.416 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 853.296 M | 917.658 M | 982.318 M | 1.056 B | 1.074 B | 1.138 B | 1.240 B | 1.334 B | |
| Total liabilities | 54.054 M | 78.765 M | 96.472 M | 109.458 M | 89.742 M | 97.747 M | 102.218 M | 114.234 M | |
| Total current liabilities | 47.589 M | 71.851 M | 89.527 M | 101.995 M | 79.489 M | 86.896 M | 91.268 M | 102.942 M | |
| Accounts Payable | 34.870 M | 48.757 M | 58.690 M | 63.974 M | 30.722 M | 33.641 M | 33.801 M | 42.990 M | |
| Other liabilities | 6.465 M | 6.914 M | 6.945 M | 7.463 M | 10.253 M | 10.851 M | 10.950 M | 11.292 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 6.465 M | 6.914 M | 6.945 M | 7.463 M | 10.253 M | 10.851 M | 10.950 M | 11.292 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 799.242 M | 838.893 M | 885.846 M | 946.380 M | 984.674 M | 1.041 B | 1.138 B | 1.220 B | |
| Common stock | 1.068 B | 1.093 B | 1.110 B | 1.127 B | 1.129 B | 1.146 B | 1.164 B | 1.194 B | |
| Retained earnings | -268.895 M | -253.327 M | -226.147 M | -180.668 M | -144.935 M | -106.602 M | -27.237 M | 24.163 M |